← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Nanovalent Pharmaceuticals, Inc.
Bozeman, MT
$7,297,578
Total funding
7
Grants
Funding over time
peak $1.8M · FY2012–25$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,622,730 · 5
NSF$674,848 · 2
By mechanism
R44$3,743,252 · 2
R42$2,400,000 · 1
—$674,848 · 2
R41$479,478 · 2
Investigators at Nanovalent Pharmaceuticals, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
NV103: Antibody Conjugated Nanoparticle for Ewing Sarcoma Targeted Therapy$1,019,254
R44 · FY2019 · CA
Tumor Antigen Targeted Nanoparticle Therapy for Glioblastoma (GBM)$1,000,000
R42 · FY2024 · CA
Tumor Antigen Targeted Nanoparticle Therapy for Glioblastoma (GBM)$1,000,000
R42 · FY2025 · CA
NV103: Antibody Conjugated Nanoparticle for Ewing Sarcoma Targeted Therapy$892,769
R44 · FY2020 · CA
Targeted Polymerized Shell Microbubbles to Image and Treat Surgical Adhesions$831,190
R44 · FY2018 · GM
Targeted Polymerized Shell Microbubbles to Image and Treat Surgical Adhesions$759,290
R44 · FY2019 · GM
SBIR Phase II: Targeted Nanoparticle Delivery Agent for Treatment of Adult Leukemia$510,000
· FY2013 · TIP
Tumor Antigen Targeted Nanoparticle Therapy for Glioblastoma (GBM)$400,000
R42 · FY2023 · CA
Nanoparticle Delivery System for Ewing Sarcoma Treatment$240,750
R41 · FY2016 · CA
NV103: Antibody Conjugated Nanoparticle for Ewing Sarcoma Targeted Therapy$240,749
R44 · FY2018 · CA
Targeted Polymerized Shell Microbubbles to Image Surgical Adhesions$238,728
R41 · FY2016 · GM
SBIR Phase I: Targeted Nanoparticle Delivery Agent for Treatment of Adult Leukemia$164,848
· FY2012 · TIP